

CytoSorbents Cp

(CTSO- NASDAQ)

Current Recommendation	Outperform
Prior Recommendation	Neutral
Date of Last Change	02/02/2015
Current Price (02/02/15)	\$8.11
Target Price	\$12.50

OUTLOOK

CytoSorb was CE Marked in March 2011 and subsequently commenced its initial commercialization. Initial focus on building awareness appears to be paying off. CTSO now generating clinical outcomes data which is just starting to be used to accelerate adoption and utilization. CTSO now expects to pursue cardiac surgery indication in the U.S. as this may provide the lowest cost, easiest and fastest route to the U.S. market. Cardiac surgery indication has driven substantial interest overseas with successful outcomes. Gov't contracts/grants that CTSO continues to score should benefit near-term revenue and cash flow as well as also aid their awareness-building efforts, further increase visibility and credibility of the technology, and potentially expand the menu of potential applications of the device. Interest in and use of CytoSorb from hospitals and physicians continues to increase. Also seeing great interest from distributors and other industry partners.

SUMMARY DATA

52-Week High	\$12.87
52-Week Low	\$4.40
One-Year Return (%)	106.25
Beta	-1.65
Average Daily Volume (sh)	32,605

Shares Outstanding (mil)	23
Market Capitalization (\$mil)	\$154
Short Interest Ratio (days)	N/A
Institutional Ownership (%)	0
Insider Ownership (%)	24

Annual Cash Dividend	\$0.00
Dividend Yield (%)	0.00

5-Yr. Historical Growth Rates	
Sales (%)	N/A
Earnings Per Share (%)	N/A
Dividend (%)	N/A

P/E using TTM EPS	N/A
P/E using 2014 Estimate	N/A
P/E using 2015 Estimate	N/A

Zacks Rank	N/A
------------	-----

Risk Level	Above Avg.,
Type of Stock	N/A
Industry	Med Products

ZACKS ESTIMATES

Revenue

(in '000 of \$)

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2013	371 A	292 A	881 A	879 A	2423 A
2014	1062 A	1025 A	1162 A	1587 E	4836 E
2015					14210 E
2016					22380 E

Earnings per Share

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2013	-0.25 A	-0.22 A	-0.15 A	-0.18 A	-0.75 A
2014	-0.20 A	-0.27 A	-0.22 A	-0.11 E	-0.73 E
2015					-0.24 E
2016					-0.14 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

FDA Approves Cardiac Surgery Feasibility Study

FDA's approval for CytoSorbents to conduct a feasibility study comes about one month after the company submitted its investigational device exemption. This morning's press release provides some details on the study design. The study is expected to enroll 20 patients undergoing cardiac surgery across three (unnamed) U.S. sites and, along with safety, will evaluate CytoSorb's ability to actively remove plasma free hemoglobin and cytokines, among other inflammatory markers. These toxic substances, which are produced during cardiac surgery, can lead to serious complications including kidney injury / failure.

While this is a single-arm study, CTSO will also conduct a parallel, non-interventional study across several U.S. cardiac surgery centers. This study will use similar enrollment criteria as the interventional study and collect similar data related to adverse events, such as kidney injury / failure, and inflammatory markers, such as plasma free hemoglobin and cytokines from a broad population of patients undergoing cardiac surgery.

The two studies will provide a comparison of how well CytoSorb was able to reduce toxic substances and related adverse events between the active study patient population and those undergoing cardiac surgery where CytoSorb was not used. This data, assuming positive, will then be used as support for regulatory approval to initiate a larger, pivotal study for support of FDA approval. CTSO expects to commence this feasibility study shortly after receiving requisite institutional review board approvals at the selected study sites.

CytoSorbents already has early data on efficacy of CytoSorb in reduction of inflammatory biomarkers, which includes that from the study done in Germany and published in the journal *Kardiotechnik* - results of which showed CytoSorb effectively reduced levels of certain inflammatory biomarkers. In addition to this study, CTSO has had successful results with in vitro studies as well. CytoSorb has also been used successfully by clinicians in Europe in certain cardiac surgery settings and is now being used in a cardiac surgery study in Austria, data from which is expected to be forthcoming. A larger 200-patient (100 treatment / 100 control) cardiac surgery study recently commenced in Germany. Management expects data from these various sources to be available in the coming quarters which could very well provide even more support for use of CytoSorb in this indication and, along with data from the feasibility study, provide additional insight into the approvability of the device in the U.S.

We are reiterating our Outperform rating on CTSO as well as our \$12.50/share price target.


FINANCIAL MODEL

CytoSorbents Inc.

	2013 A	Q1A	Q2A	Q3A	Q4E	2014 E	2015 E	2016 E	2017 E
CytoSorb Sales	\$821.8	\$569.2	\$663.2	\$1,031.8	\$1,180.0	\$3,444.2	\$13,110.0	\$22,180.0	\$30,090.0
<i>y-o-y growth</i>	442.1%	223.3%	418.3%	406.9%	275.6%	319.1%	280.6%	69.2%	35.7%
Total Royalties/Grants/Other	\$1,600.9	\$492.9	\$361.4	\$130.6	\$407.0	\$1,391.9	\$1,100.0	\$200.0	\$0.0
<i>y-o-y growth</i>	34.4%	152.5%	121.0%	-80.7%	-28.0%	-13.1%	-21.0%	-81.8%	-100.0%
Revenue	\$2,422.7	\$1,062.2	\$1,024.7	\$1,162.3	\$1,587.0	\$4,836.2	\$14,210.0	\$22,380.0	\$30,090.0
<i>YOY Growth</i>	80.4%	186.0%	251.5%	32.0%	80.5%	99.6%	193.8%	57.5%	34.5%
Cost of Goods Sold	\$1,911.6	\$662.5	\$666.2	\$475.9	\$847.6	\$2,652.2	\$6,154.8	\$8,658.4	\$11,434.2
Gross Income	\$511.1	\$399.6	\$358.5	\$686.5	\$739.4	\$2,184.0	\$8,055.2	\$13,721.6	\$18,655.8
<i>Gross Margin</i>	21.1%	37.6%	35.0%	59.1%	46.6%	45.2%	56.7%	61.3%	62.0%
SG&A	\$3,485.4	\$1,317.1	\$1,394.6	\$1,492.5	\$1,664.0	\$5,868.2	\$9,654.0	\$13,236.0	\$15,616.7
<i>% SG&A</i>	143.9%	124.0%	136.1%	128.4%	104.9%	121.3%	67.9%	59.1%	51.9%
R&D	\$1,738.9	\$236.8	\$347.0	\$880.3	\$862.0	\$2,326.1	\$4,500.0	\$4,200.0	\$3,287.0
<i>% R&D</i>	71.8%	22.3%	33.9%	75.7%	54.3%	48.1%	31.7%	18.8%	10.9%
Operating Income	(\$4,713.2)	(\$1,154.2)	(\$1,383.1)	(\$1,686.4)	(\$1,786.6)	(\$6,010.2)	(\$6,098.8)	(\$3,714.4)	(\$247.9)
<i>Operating Margin</i>	-	-	-	-	-	-	-	-	-
Total Other Expense	\$422.8	(\$179.1)	\$470.5	(\$188.0)	(\$47.0)	\$56.4	\$0.0	\$0.0	\$0.0
Pre-Tax Income	(\$5,136.1)	(\$975.1)	(\$1,853.6)	(\$1,498.4)	(\$1,739.6)	(\$6,066.6)	(\$6,098.8)	(\$3,714.4)	(\$247.9)
Taxes (benefit)	(\$458.3)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
<i>Tax Rate</i>	8.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Preferred Dividend	\$2,395.5	\$1,114.5	\$1,374.2	\$1,281.1	\$701.0	\$4,470.8	\$0.0	\$0.0	\$0.0
Net Income	(\$7,073.3)	(\$2,089.6)	(\$3,227.8)	(\$2,779.4)	(\$2,440.6)	(\$10,537.4)	(\$6,098.8)	(\$3,714.4)	(\$247.9)
<i>Net Margin</i>	-	-196.7%	-315.0%	-239.1%	-153.8%	-	-42.9%	-16.6%	-0.8%
EPS	(\$0.75)	(\$0.20)	(\$0.27)	(\$0.22)	(\$0.11)	(\$0.73)	(\$0.24)	(\$0.14)	(\$0.01)
<i>YOY Growth</i>	-	-	-	-	-	-	-	-	-
Diluted Shares O/S	9,441	10,619	12,048	12,496	22,600	14,441	25,000	25,900	26,800

Brian Marckx, CFA

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brian Marckx, CFA, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1120 companies whose securities it covers, including securities covered by Zacks SCR:

Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.

Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.

Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 15.6%, Hold/Neutral- 77.0%, Sell/Underperform – 6.7%. Data is as of midnight on the business day immediately prior to this publication.